217 related articles for article (PubMed ID: 17208382)
1. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
Strous RD; Stryjer R; Maayan R; Gal G; Viglin D; Katz E; Eisner D; Weizman A
Psychoneuroendocrinology; 2007 Feb; 32(2):96-105. PubMed ID: 17208382
[TBL] [Abstract][Full Text] [Related]
2. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.
Strous RD; Maayan R; Lapidus R; Stryjer R; Lustig M; Kotler M; Weizman A
Arch Gen Psychiatry; 2003 Feb; 60(2):133-41. PubMed ID: 12578430
[TBL] [Abstract][Full Text] [Related]
4. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
Nachshoni T; Ebert T; Abramovitch Y; Assael-Amir M; Kotler M; Maayan R; Weizman A; Strous RD
Schizophr Res; 2005 Nov; 79(2-3):251-6. PubMed ID: 16126372
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA.
Ritsner MS; Strous RD
J Psychiatr Res; 2010 Jan; 44(2):75-80. PubMed ID: 19665142
[TBL] [Abstract][Full Text] [Related]
6. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
7. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.
Kotler M; Strous RD; Reznik I; Shwartz S; Weizman A; Spivak B
Int Clin Psychopharmacol; 2004 Jan; 19(1):23-6. PubMed ID: 15101566
[TBL] [Abstract][Full Text] [Related]
8. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Smith RC; Infante M; Singh A; Khandat A
Int J Neuropsychopharmacol; 2001 Sep; 4(3):239-50. PubMed ID: 11669086
[TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
10. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
13. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
McGlashan TH; Zipursky RB; Perkins D; Addington J; Miller T; Woods SW; Hawkins KA; Hoffman RE; Preda A; Epstein I; Addington D; Lindborg S; Trzaskoma Q; Tohen M; Breier A
Am J Psychiatry; 2006 May; 163(5):790-9. PubMed ID: 16648318
[TBL] [Abstract][Full Text] [Related]
15. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
16. Alterations in DHEA metabolism in schizophrenia: two-month case-control study.
Ritsner M; Gibel A; Ram E; Maayan R; Weizman A
Eur Neuropsychopharmacol; 2006 Feb; 16(2):137-46. PubMed ID: 16139994
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
18. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
Perlick DA; Rosenheck RA; Kaczynski R; Bingham S; Collins J
Schizophr Res; 2008 Feb; 99(1-3):192-9. PubMed ID: 17851042
[TBL] [Abstract][Full Text] [Related]
19. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.
Voruganti LP; Awad AG; Parker G; Forrest C; Usmani Y; Fernando ML; Senthilal S
Schizophr Res; 2007 Nov; 96(1-3):146-55. PubMed ID: 17728106
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
Silva de Lima M; de Jesus Mari J; Breier A; Maria Costa A; Pondé de Sena E; Hotopf M
J Clin Psychiatry; 2005 Jul; 66(7):831-8. PubMed ID: 16013897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
